Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBIT: 2021-2025

Historic EBIT for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.8 million.

  • InMed Pharmaceuticals' EBIT fell 4.94% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 10.66%. This contributed to the annual value of -$7.9 million for FY2025, which is 3.05% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported EBIT of -$1.8 million as of Q3 2025, which was down 0.04% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year EBIT high stood at -$485,150 for Q2 2023, and its period low was -$6.5 million during Q2 2022.
  • Moreover, its 3-year median value for EBIT was -$1.8 million (2024), whereas its average is -$1.9 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' EBIT skyrocketed by 92.56% in 2023, and later plummeted by 319.30% in 2024.
  • InMed Pharmaceuticals' EBIT (Quarterly) stood at -$4.3 million in 2021, then surged by 48.31% to -$2.2 million in 2022, then increased by 25.70% to -$1.6 million in 2023, then tumbled by 37.03% to -$2.3 million in 2024, then decreased by 4.94% to -$1.8 million in 2025.
  • Its EBIT stands at -$1.8 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.1 million for Q1 2025.